Busulfan

• A Phase 3 Study to Evaluate Efficacy and Safety of a Single Dose of Exa-cel in Subjects with Severe Sickle Cell Disease, βS/βC Genotype Pending
  2023-503247-34-00 Phase III 2 countries Vertex Pharmaceuticals Inc.
• Prospective multicenter clinical trial for risk estimation and treatment stratification in low and intermediate risk neuroblastoma patients … Pending
  2024-517295-37-00 Phase III 1 country University Of Cologne
• A single arm, open label, multicenter, single-dose, phase 2b clinical study evaluating efficacy and safety of gene therapy using autologous … Pending
  2025-522160-32-00 Phase II 1 country Fondazione Telethon Ets; San Raffaele Hospital
• Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALL. Recruiting
  2025-522052-13-00 Phase II/III 9 countries Ospedale Pediatrico Bambino Gesu
• ALL SCTped 2012 FORUM - Allogeneic Stem Cell Transplantation in Children and Adolescents with Acute Lymphoblastic Leukaemia Recruiting
  2024-512657-24-00 Phase II/III 12 countries St. Anna Childrens Cancer Research Institute GmbH
• Registry and clinical trial comparing standard intensity and reduced intensity treatment in patients with AML or CLL who do not have residua… Recruiting
  2024-512503-39-00 Phase IV 3 countries Medizinische Hochschule Hannover
• HR-NBL2: High-risk neuroblastoma study 2.0 of SIOP-Europe- Neuroblastoma/SIOPEN: Randomised, international and multicentric phase 3 study t… Recruiting
  2024-514917-36-00 Phase III 13 countries Institut Gustave Roussy
• A Clinical Study to Evaluate the Use of a Cryopreserved Formulation of OTL-103 in Subjects with WAS. Recruiting
  2024-517792-20-00 Phase III 1 country Fondazione Telethon Ets
• Randomized Phase 2 study testing two conditioning regimen with a single prophylaxis of graft-versus-host disease by cyclophosphamide and met… Recruiting
  2023-509042-35-01 Phase II 1 country Centre Hospitalier Universitaire De Nantes
• Bomedemstat vs Best Available Therapy (BAT) for Essential Thrombocythemia Recruiting
  2023-504865-21-00 Phase III 10 countries Merck Sharp & Dohme LLC
• FLUCLORIC - Randomized multicentric Phase III study comparing the efficacy of two reduced intensity conditioning regimens (clofarabine/busul… Recruiting
  2022-502019-12-00 Phase III 1 country Centre Hospitalier Universitaire De Nantes
• Age-adjusted high-dose chemotherapy followed by autologous stem cell transplantation or conventional chemotherapy with R-MP as first-line tr… Recruiting
  2024-512320-11-00 Phase III 2 countries Medical Center - University Of Freiburg
• International multicenter, open-label clinical trial for the treatment of acute myeloid leukemia in children and adolescents Recruiting
  2022-500783-35-00 Phase III 6 countries GPOH gGmbH
• A Phase 3b Study to Evaluate Efficacy and Safety of a Single Dose of Autologous CRISPR Cas9 Modified CD34+ Human Hematopoietic Stem and Prog… Recruiting
  2024-514641-12-00 Phase III 2 countries Vertex Pharmaceuticals Inc.
• A Phase 3 Study to Evaluate the Safety and Efficacy of a Single Dose of CTX001 in Pediatric Subjects With Severe Sickle Cell Disease Recruiting
  2024-513978-22-00 Phase III 2 countries Vertex Pharmaceuticals Inc.
• Studying Conditioning Regimen In Pediatric Transplantation -AML Recruiting
  2023-505512-37-00 Phase III 6 countries Vaestra Goetalandsregionen
• A Phase 3 Study to Evaluate the Safety and Efficacy of a Single Dose of CTX001 in Pediatric Subjects With Transfusion-Dependent β-Thalassemi… Recruiting
  2024-513349-35-00 Phase III 2 countries Vertex Pharmaceuticals Inc.
• The study is aimed at evaluating the feasibility of a hypomethylating treatment combined with hematopoietic stem cell transplantation in com… Recruiting
  2023-510515-19-00 Phase III 1 country Fondazione Gimema Franco Mandelli Onlus
• Study to determine the efficacy of Gemtuzumab Ozogamicin, together with standard chemotherapy, on minimal residual disease levels, in adult … Recruiting
  2023-510433-29-00 Phase III 1 country Fondazione Gimema Franco Mandelli Onlus
• A study to investigate the efficacy and safety of OTL-203 in subjects with mucopolysaccharidosis type I, Hurler syndrome (MPS-IH) compared w… Ended
  2022-500306-17-00 Phase III 2 countries Orchard Therapeutics (Europe) Limited
• Optimizing MATRix, a combination of Methotrexate, Ara-C, Thiotepa and Rituximab given as an induction therapy, de-escalated in duration and … Ended
  2024-514473-21-00 Phase III 3 countries Klinikum Der Landeshauptstadt Stuttgart gKAöR
• Gene therapy study with autologous hematopoietic stem cells for patients affected by MPS-IH Ended
  2024-514870-29-00 Phase I (FiH) 1 country Orchard Therapeutics (Europe) Limited
• Myechild 01: International Randomised Phase III Clinical Trial in Children with Acute Myeloid Leukaemia - Incorporating an Embedded Dose Fin… Ended
  2024-516112-21-00 Phase III 2 countries The University Of Birmingham
• Prospective and multicentre evaluation of 3 different doses of IV busulfan associated with fludarabine and thymoglobuline in the conditionin… Ended
  2024-516435-27-00 Phase II 1 country Institut Paoli Calmettes

Showing 1–24 of 29 trials